{"id":501665,"date":"2021-06-08T07:12:36","date_gmt":"2021-06-08T11:12:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/"},"modified":"2021-06-08T07:12:36","modified_gmt":"2021-06-08T11:12:36","slug":"foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/","title":{"rendered":"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera"},"content":{"rendered":"
\n

Personalized technology aims to address both early- and advanced-stage cancer monitoring applications<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CAMBRIDGE, Mass.<\/span> and AUSTIN, Texas<\/span>, June 8, 2021<\/span> \/PRNewswire\/ —\u00a0Foundation Medicine, Inc.<\/a>\u00a0and Natera, Inc.<\/a>\u00a0(NASDAQ: NTRA), today\u00a0announced\u00a0the launch of the research use version of FoundationOne\u00ae<\/sup>Tracker,\u00a0Foundation Medicine’s\u00a0personalized\u00a0circulating tumor DNA (ctDNA)\u00a0monitoring assay.\u00a0FoundationOne\u00a0Tracker uniquely combines Foundation Medicine’s tissue-based\u00a0comprehensive genomic profiling (CGP)\u00a0platform\u00a0with Natera’s expertise in ctDNA monitoring.\u00a0<\/p>\n

\n

\n
\n \"Natera,
\n <\/a>\n <\/p>\n<\/p><\/div>\n

FoundationOne Tracker uses optimized algorithms for identifying tumor-specific variants and a personalized assay design that allows for the detection of ctDNA in plasma for use in both advanced- \u00a0and early-stage research applications.\u00a0Additionally, the creation of a robust, fully integrated workflow between Foundation Medicine and Natera is expected to provide rapid inclusion of ctDNA monitoring results into retrospective research studies. <\/p>\n

“The addition of\u00a0FoundationOne\u00a0Tracker for research use provides our biopharma and academic partners\u00a0access to Foundation Medicine’s broad, advanced-stage\u00a0CGP footprint,” said Foundation Medicine’s Chief Scientific Officer Priti Hegde<\/span>. “In\u00a0partnering with Natera, we have been\u00a0able to leverage the best of both of our technologies to provide a cost-effective and efficient path to bring more personalized monitoring tools to our partners, and down the line, to physicians and patients, to help inform their treatment strategy.”\u00a0<\/p>\n

“This partnership will help accelerate personalized ctDNA monitoring as the new standard of care in oncology,” said Solomon Moshkevich<\/span>, Natera’s general manager of oncology. “With Foundation Medicine’s strong track record of scientific leadership and its broad footprint within biopharma, we expect FoundationOne Tracker to become an important new tool for accelerating and improving drug development in oncology.”<\/p>\n

\n About Foundation Medicine<\/b>\u00a0
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please\u00a0visit\u202fwww.FoundationMedicine.com<\/a>\u202for follow Foundation Medicine on Twitter\u202f(@FoundationATCG<\/a>).\u00a0<\/p>\n

\n Foundation Medicine\u00ae<\/sup><\/i>
\n
\n \u202f<\/sup>
\n <\/i>
\n and\u00a0FoundationOne\u00ae<\/sup>\u202fare\u00a0registered trademarks\u00a0of Foundation Medicine, Inc.<\/i>\u00a0<\/p>\n

\n About Natera
<\/b>
\n Natera<\/a>\u00a0is a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas<\/span> and San Carlos, California<\/span>. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com<\/a>. Follow Natera on LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements
<\/b>All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical or other studies will support the use of our product offerings, our collaborations with commercial partners such as pharmaceutical companies, medical institutions, contract laboratories, laboratory partners, and other third parties, our ability to successfully execute the partnership and co-develop the assay, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com\/investors<\/a> and www.sec.gov<\/a>.<\/p>\n

\n Foundation Medicine Contact:<\/b>\u00a0
Abigail Alderman<\/span>, 781-534-3210\u00a0
pr@foundationmedicine.com\u00a0
<\/a>\u00a0<\/p>\n

\n Natera Contacts:
<\/b>Investor Relations: Mike Brophy<\/span>, CFO, Natera, Inc., 650-249-9090
Media: Kate Stabrawa<\/span>, Communications, Natera, Inc., 720-318-4080 pr@natera.com<\/a> \u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-301307439.html<\/a><\/p>\n

SOURCE Natera, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Personalized technology aims to address both early- and advanced-stage cancer monitoring applications PR Newswire CAMBRIDGE, Mass. and AUSTIN, Texas, June 8, 2021 \/PRNewswire\/ —\u00a0Foundation Medicine, Inc.\u00a0and Natera, Inc.\u00a0(NASDAQ: NTRA), today\u00a0announced\u00a0the launch of the research use version of FoundationOne\u00aeTracker,\u00a0Foundation Medicine’s\u00a0personalized\u00a0circulating tumor DNA (ctDNA)\u00a0monitoring assay.\u00a0FoundationOne\u00a0Tracker uniquely combines Foundation Medicine’s tissue-based\u00a0comprehensive genomic profiling (CGP)\u00a0platform\u00a0with Natera’s expertise in ctDNA monitoring.\u00a0 FoundationOne Tracker uses optimized algorithms for identifying tumor-specific variants and a personalized assay design that allows for the detection of ctDNA in plasma for use in both advanced- \u00a0and early-stage research applications.\u00a0Additionally, the creation of a robust, fully integrated workflow between Foundation Medicine and Natera is expected to provide rapid inclusion of ctDNA monitoring results into retrospective research studies. “The addition of\u00a0FoundationOne\u00a0Tracker for research … <\/p>\n

Continue reading “Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-501665","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFoundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Personalized technology aims to address both early- and advanced-stage cancer monitoring applications PR Newswire CAMBRIDGE, Mass. and AUSTIN, Texas, June 8, 2021 \/PRNewswire\/ —\u00a0Foundation Medicine, Inc.\u00a0and Natera, Inc.\u00a0(NASDAQ: NTRA), today\u00a0announced\u00a0the launch of the research use version of FoundationOne\u00aeTracker,\u00a0Foundation Medicine’s\u00a0personalized\u00a0circulating tumor DNA (ctDNA)\u00a0monitoring assay.\u00a0FoundationOne\u00a0Tracker uniquely combines Foundation Medicine’s tissue-based\u00a0comprehensive genomic profiling (CGP)\u00a0platform\u00a0with Natera’s expertise in ctDNA monitoring.\u00a0 FoundationOne Tracker uses optimized algorithms for identifying tumor-specific variants and a personalized assay design that allows for the detection of ctDNA in plasma for use in both advanced- \u00a0and early-stage research applications.\u00a0Additionally, the creation of a robust, fully integrated workflow between Foundation Medicine and Natera is expected to provide rapid inclusion of ctDNA monitoring results into retrospective research studies. “The addition of\u00a0FoundationOne\u00a0Tracker for research … Continue reading "Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-08T11:12:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/286881\/Natera_Inc___Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera\",\"datePublished\":\"2021-06-08T11:12:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/\"},\"wordCount\":774,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/286881\\\/Natera_Inc___Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/\",\"name\":\"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/286881\\\/Natera_Inc___Logo.jpg\",\"datePublished\":\"2021-06-08T11:12:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/286881\\\/Natera_Inc___Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/286881\\\/Natera_Inc___Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/","og_locale":"en_US","og_type":"article","og_title":"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera - Market Newsdesk","og_description":"Personalized technology aims to address both early- and advanced-stage cancer monitoring applications PR Newswire CAMBRIDGE, Mass. and AUSTIN, Texas, June 8, 2021 \/PRNewswire\/ —\u00a0Foundation Medicine, Inc.\u00a0and Natera, Inc.\u00a0(NASDAQ: NTRA), today\u00a0announced\u00a0the launch of the research use version of FoundationOne\u00aeTracker,\u00a0Foundation Medicine’s\u00a0personalized\u00a0circulating tumor DNA (ctDNA)\u00a0monitoring assay.\u00a0FoundationOne\u00a0Tracker uniquely combines Foundation Medicine’s tissue-based\u00a0comprehensive genomic profiling (CGP)\u00a0platform\u00a0with Natera’s expertise in ctDNA monitoring.\u00a0 FoundationOne Tracker uses optimized algorithms for identifying tumor-specific variants and a personalized assay design that allows for the detection of ctDNA in plasma for use in both advanced- \u00a0and early-stage research applications.\u00a0Additionally, the creation of a robust, fully integrated workflow between Foundation Medicine and Natera is expected to provide rapid inclusion of ctDNA monitoring results into retrospective research studies. “The addition of\u00a0FoundationOne\u00a0Tracker for research … Continue reading \"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-08T11:12:36+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/286881\/Natera_Inc___Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera","datePublished":"2021-06-08T11:12:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/"},"wordCount":774,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/286881\/Natera_Inc___Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/","name":"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/286881\/Natera_Inc___Logo.jpg","datePublished":"2021-06-08T11:12:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/286881\/Natera_Inc___Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/286881\/Natera_Inc___Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foundation-medicine-launches-foundationonetracker-ctdna-monitoring-assay-for-research-use-in-partnership-with-natera-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foundation Medicine Launches FoundationOne\u00aeTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/501665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=501665"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/501665\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=501665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=501665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=501665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}